Prescription Libido Treatments for Women: What's FDA-Approved, What's Off-Label, and How to Get Evaluated

The short answer

That distinction matters before you spend money. Neither Addyi nor Vyleesi is FDA-approved for postmenopausal women. For postmenopausal women with HSDD, the 2019 Global Consensus Position Statement supports a carefully monitored trial of testosterone, but there is no testosterone product FDA-approved for women, so any such prescription is off-label and dosed by a clinician. Vaginal estrogen and vaginal DHEA are real prescription treatments, but they treat painful sex and vaginal dryness, which is a different problem from low desire.

The most useful thing to understand up front is that desire problems are usually multifactorial. Relationship strain, mood, sleep, other medications (including some antidepressants), and physical pain during sex all suppress desire, and none of them are fixed by a libido pill. The American College of Obstetricians and Gynecologists frames sexual concerns as something to evaluate with a clinician first, because the right treatment depends on the underlying cause. This page explains each approved drug, its label warnings, the off-label options, and how the cost and access pathways actually work so you can have an informed conversation with a licensed prescriber.

What HSDD actually is, and why the diagnosis gates the prescription

Hypoactive sexual desire disorder is not simply having a lower libido than you used to, or a lower libido than a partner. It refers to a persistent lack of sexual desire that causes personal distress and is not better explained by another medical condition, a relationship problem, or a medication. The word acquired means the low desire developed after a period of normal desire, rather than being lifelong. The word generalized means it happens across situations and partners, rather than being specific to one relationship or context.

These qualifiers are not academic. The FDA labels for both approved drugs specify acquired, generalized HSDD, so a prescriber is meant to confirm that pattern before prescribing. A clinical review of HSDD in the Journal of Midwifery and Women's Health describes assessment as a structured process that screens for distress and rules out other explanations, which is why a legitimate evaluation asks about mood, medications, pain, and relationship context rather than just handing over a pill.

Distress is the pivot point. Low desire that does not bother you is not a disorder and does not require treatment. Low desire that genuinely distresses you is what these medications are studied to address. If a service offers to prescribe without ever assessing distress or cause, that is a sign it is selling a product rather than treating a condition.

Flibanserin (Addyi): the daily pill

Flibanserin, sold as Addyi, is a once-daily oral tablet taken at bedtime. It is approved for acquired, generalized HSDD in premenopausal women. Unlike erectile-dysfunction drugs, it is not taken before sex and does not work on demand; it acts on brain neurotransmitter systems and is meant to be taken continuously. Its prescribing information directs that treatment be discontinued after eight weeks if a woman does not report improvement, which means it is not something to keep paying for indefinitely without benefit.

The bedtime dosing is a safety instruction, not a convenience. Flibanserin's label warns about hypotension (low blood pressure) and syncope (fainting), and taking it at bedtime reduces the risk of injury from those effects. The label is explicit that the risk is increased with alcohol and with certain interacting medications, particularly moderate or strong CYP3A4 inhibitors, which can raise flibanserin levels in the body.

Because of these interactions, flibanserin is not a casual purchase. A prescriber needs to review your full medication list, including some antifungals, certain antibiotics, and other common drugs, because combining them with flibanserin can be dangerous. Any online seller willing to ship it without that review is skipping the exact safety step the FDA label was built around.

The alcohol and interaction warnings on Addyi, in plain terms

Alcohol is the headline safety issue with flibanserin. The prescribing information addresses the combination of flibanserin and alcohol because together they can lower blood pressure and cause fainting. This is not the same as the general advice to drink moderately; it is a specific drug-plus-alcohol interaction that a prescriber must discuss with you before you start.

The drug-interaction warnings extend beyond alcohol. Moderate and strong CYP3A4 inhibitors can increase how much flibanserin ends up in your bloodstream, amplifying the blood-pressure and fainting risks. This is why the medication has historically been dispensed with counseling and why a real evaluation reviews everything you take, including supplements and grapefruit-type interactions that affect the same liver enzyme.

The practical takeaway is that flibanserin is a reasonable option for some premenopausal women, but only after a prescriber has confirmed the diagnosis, reviewed your medications, and talked through the alcohol interaction. A quiz-and-ship model that never has that conversation is not delivering the standard of care the label describes.

Bremelanotide (Vyleesi): the as-needed injection

Bremelanotide, sold as Vyleesi, is a different kind of treatment. It is approved for the same population, premenopausal women with acquired, generalized HSDD, but it is used as needed rather than daily. It is a subcutaneous injection given with an autoinjector pen into the abdomen or thigh at least 45 minutes before anticipated sexual activity. Because it is episodic, it suits women who do not want to take a daily medication.

Bremelanotide activates melanocortin receptors, a pathway involved in sexual response. A review in CNS Spectrums describes the neurobiology of this melanocortin mechanism, which is distinct from how flibanserin works on serotonin, dopamine, and norepinephrine systems. The label limits use to no more than one dose within 24 hours and no more than eight doses per month, so it is not intended for very frequent use.

The most common side effect on the Vyleesi label is nausea, which can occur after the first dose and lead some women to stop treatment. The label also notes transient increases in blood pressure and decreases in heart rate after dosing, which is why it is not recommended for women with uncontrolled high blood pressure or known cardiovascular disease. It can also cause darkening of the skin or gums in some users, more likely with more frequent dosing.

Addyi versus Vyleesi: how the two approved drugs compare

The two drugs are approved for the same diagnosis but differ in almost every practical dimension: how you take them, when they act, and what side effects dominate. The table below summarizes the label-level differences so you can see which format fits your life before discussing specifics with a prescriber.

Neither drug is a guaranteed fix, and both labels build in stopping rules or usage caps, which is a signal that response varies between women and should be monitored rather than assumed. The choice between a continuous daily pill and an episodic injection often comes down to your tolerance for daily dosing, your alcohol use, and your cardiovascular history.

Postmenopausal women: the off-label testosterone question

If you are postmenopausal, the two FDA-approved libido drugs are, by their labels, not approved for you. This is one of the most misunderstood points in the market, because plenty of services advertise libido treatment broadly without noting that the approvals stop at premenopausal HSDD.

For postmenopausal women with HSDD, the best available guidance is the 2019 Global Consensus Position Statement on the use of testosterone therapy for women, which supports a trial of testosterone at physiologic doses for this specific indication. The North American Menopause Society's 2022 hormone therapy position statement similarly addresses the role of hormones in midlife women. But the consensus also underscores a hard limitation: there is no testosterone product approved by the FDA for women. That means any testosterone prescribed for female desire is off-label, often adapted from male products at much lower doses or compounded, and requires baseline and follow-up blood testing to keep levels in a physiologic range.

Off-label is not the same as illegitimate; it means the use falls outside the approved labeling and depends heavily on prescriber judgment and monitoring. The consensus statement supports testosterone only for HSDD, not as a general wellness booster, anti-aging tool, or energy supplement, and it does not endorse the high-dose pellets and unmonitored regimens some clinics promote. If a provider offers testosterone without measuring your levels or without a clear HSDD rationale, that is a departure from the evidence the consensus is built on.

Vaginal estrogen and DHEA: the right drug for a different problem

Vaginal estrogen and vaginal DHEA (prasterone) are legitimate prescription treatments, but they are not libido drugs. They treat genitourinary symptoms of menopause: vaginal dryness, thinning tissue, and pain during sex. This matters because pain during sex is itself a powerful suppressor of desire, so for some women the path to wanting sex again runs through fixing the pain, not through a desire drug.

This is exactly why a clinician evaluation is worth the step. If low desire is downstream of painful sex, a desire medication may do nothing while a local estrogen or DHEA treatment resolves the root cause. The NAMS 2022 position statement covers the role of estrogen therapies in menopause, including local vaginal preparations that act on tissue with minimal systemic absorption.

Confusing these categories wastes money and time. A product marketed vaguely for female sexual wellness might be a vaginal moisturizer, a hormone, an approved desire drug, or an unapproved supplement, and they address entirely different problems. Knowing which problem you actually have, low desire versus painful or uncomfortable sex, is the first thing a good evaluation sorts out.

Why the evaluation comes before the prescription

Desire is multifactorial, which is a clinical way of saying many separate things feed into it. Mood disorders and the antidepressants used to treat them, chronic stress, poor sleep, relationship conflict, thyroid and other hormonal conditions, alcohol, and numerous medications can each lower desire independently. A pill aimed at one pathway cannot correct a cause it does not touch.

ACOG's patient guidance treats sexual health as something to raise with a clinician, who can assess whether the concern is about desire, arousal, pain, or orgasm, since these are distinct and have distinct treatments. That triage is the reason a serious evaluation asks a lot of questions before, or instead of, reaching for a prescription. Sometimes the most effective intervention is changing an interacting medication or addressing sleep, not adding a new drug.

A good evaluation also screens for the things that make the approved drugs unsafe: for flibanserin, alcohol use and interacting medications; for bremelanotide, cardiovascular disease and uncontrolled blood pressure. Skipping this is not a shortcut, it is the removal of the safety layer the drug labels assume is in place.

How cost and access actually work

There is no single price for these treatments, and anyone quoting you one flat number is oversimplifying. What you pay depends on the pathway you use to obtain the medication and on whether a prescriber has evaluated you. Rather than invent figures, it is more useful to understand the structure of each pathway and what drives the cost within it, then confirm the current numbers directly with the pharmacy, your insurer, or the manufacturer's official program.

Insurance coverage for HSDD medications is inconsistent; some plans cover an approved drug with prior authorization confirming the diagnosis, and others exclude it. Manufacturer savings or copay programs, offered through the official brand channels, can change out-of-pocket cost for eligible, insured patients and are worth checking on the manufacturer's own site rather than a third-party reseller. Cash-pay telehealth prices the visit and the medication together and varies by service. Compounded testosterone for off-label postmenopausal use is priced by the compounding pharmacy and is separate from any FDA-approved product's cost. The table frames these so you know what question to ask for each.

How to get evaluated by a licensed prescriber

The right first step is a conversation with a clinician licensed in your state who can confirm whether your low desire fits acquired, generalized HSDD, rule out other causes, and review your medications and health history for the specific risks each drug carries. That can happen with your own gynecologist or primary care clinician, or through a telehealth service that provides a genuine evaluation rather than a checkout quiz.

When comparing providers, look for ones that assess distress and cause, review your full medication list, and are transparent about which treatments are FDA-approved for your menopausal status and which are off-label. A provider that reaches the same prescription for everyone, or that will not explain why a given drug fits you, is optimizing for volume rather than for your outcome.

You can compare telehealth providers and clinics licensed in your state to find one that offers a real evaluation and prescribes only when appropriate. The goal is an honest assessment of what is driving your low desire and a treatment matched to it, whether that is an approved medication, a change to an existing prescription, a treatment for painful sex, or supportive care that does not involve a new drug at all.

Safety and interactions worth confirming before you start

For flibanserin, the two safety conversations that must happen are alcohol and drug interactions. The label warns that alcohol raises the risk of dangerously low blood pressure and fainting, and that moderate to strong CYP3A4 inhibitors increase flibanserin levels. Bedtime dosing and an eight-week reassessment are built into the label to manage risk and avoid open-ended use without benefit.

For bremelanotide, the key issues are nausea, which is common and can be significant, and cardiovascular status, since the drug transiently raises blood pressure and slows heart rate. It is not recommended for women with uncontrolled hypertension or known cardiovascular disease, and dosing is capped at one dose per day and eight per month. Skin or gum darkening is more likely with frequent use.

For off-label testosterone in postmenopausal women, the safeguard is monitoring. The 2019 consensus supports physiologic dosing for HSDD with blood-level testing to avoid supraphysiologic exposure, which can cause acne, unwanted hair growth, and other effects. None of these safety steps happen if a product ships without a prescriber reviewing your health, which is the single clearest line between legitimate care and a risky purchase.

Frequently asked questions

What are the FDA-approved prescription treatments for low libido in women?

Two drugs are FDA-approved to treat low sexual desire in women, and both only for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD): flibanserin (Addyi), a once-daily bedtime pill, and bremelanotide (Vyleesi), an as-needed subcutaneous injection used before anticipated sexual activity.

Can postmenopausal women take Addyi or Vyleesi?

No. Both Addyi and Vyleesi are approved by their FDA labels for premenopausal women with acquired, generalized HSDD. Neither is FDA-approved for postmenopausal women. For postmenopausal HSDD, the 2019 Global Consensus Position Statement supports off-label testosterone under clinician supervision, but no testosterone product is FDA-approved for women.

Is there an FDA-approved testosterone for women's libido?

No. There is no testosterone product FDA-approved for women. The 2019 Global Consensus supports a monitored trial of testosterone for postmenopausal women with HSDD, but because no female product exists, it is prescribed off-label at physiologic doses with blood-level testing, not self-dosed or given as high-dose pellets.

Why can't I drink alcohol with Addyi?

Flibanserin's FDA prescribing information warns that combining it with alcohol can cause dangerously low blood pressure and fainting. The label also flags interactions with moderate and strong CYP3A4 inhibitors, which raise flibanserin levels. This is why the drug is taken at bedtime and why a prescriber must review your medications before you start.

What is the difference between low desire and painful sex?

They are different problems with different treatments. Low desire is addressed by HSDD medications like Addyi or Vyleesi in premenopausal women. Painful sex and vaginal dryness are treated with vaginal estrogen or vaginal DHEA. Because pain can itself lower desire, matching the treatment to the actual cause is what a clinician evaluation sorts out first.

Do I need a clinician evaluation before getting a prescription?

Yes, and it is the most important step. ACOG frames sexual concerns as something to assess for cause first, because desire is multifactorial, influenced by mood, medications, sleep, relationships, and pain. A real evaluation confirms the HSDD diagnosis, rules out other causes, and screens for the safety issues each drug carries before anything is prescribed.

How much do prescription libido treatments cost?

There is no single price; cost depends on the access pathway. Insurance may cover an approved drug with prior authorization, manufacturer savings programs can lower cost for eligible insured patients, cash-pay telehealth bundles the visit and medication, and compounded off-label testosterone is priced separately by the pharmacy. Verify current amounts directly with your insurer, pharmacy, or the official manufacturer program.

How is Vyleesi taken?

Vyleesi (bremelanotide) is a subcutaneous injection given with an autoinjector pen into the abdomen or thigh at least 45 minutes before anticipated sexual activity. Its label limits use to one dose per 24 hours and no more than eight doses per month. The most common side effect is nausea, and it can transiently raise blood pressure and lower heart rate.

Primary sources

1. FDA Prescribing Information, Addyi (flibanserin).
2. FDA Prescribing Information, Vyleesi (bremelanotide).
3. ACOG, Your Sexual Health (patient FAQ).
4. The 2022 hormone therapy position statement of NAMS. Menopause 2022. PMID 35797481.
5. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. 2019. PMID 31498871.
6. Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment. J Midwifery Womens Health 2021. PMID 34510696.
7. The neurobiology of bremelanotide for hypoactive sexual desire disorder. CNS Spectr 2022. PMID 33455598.